High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery.

[1]  S. Robinson.  Anaphylactic Reactions to Aprotinin Reexposure in Cardiac Surgery: Relation to Antiaprotinin Immunoglobulin G and E Antibodies , 2002 .

[2]  Rick G. Smith.  Is perioperative plasma aprotinin concentration more predictable and constant after a weight-related dose regimen ? , 2001 .

[3]  M. K. Bayar,et al.  Does aprotinin reduce lung reperfusion damage after cardiopulmonary bypass? , 2000, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[4]  M. Goldman.  Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints , 2000 .

[5]  D. Haskard,et al.  Leukocyte integrin expression in patients undergoing cardiopulmonary bypass. , 2000, The Annals of thoracic surgery.

[6]  B. Eberle,et al.  Reduced inotropic support after aprotinin therapy during pediatric cardiac operations. , 1999, The Annals of thoracic surgery.

[7]  K. Kanter,et al.  Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. , 1998, The Annals of thoracic surgery.

[8]  M. Turina,et al.  Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only. , 1998, The Annals of thoracic surgery.

[9]  W. Dietrich,et al.  Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage. , 1998, The Annals of thoracic surgery.

[10]  A. Laupacis,et al.  Drugs to Minimize Perioperative Blood Loss in Cardiac Surgery: Meta-Analyses Using Perioperative Blood Transfusion As the Outcome , 1997, Anesthesia and analgesia.

[11]  G. Hill,et al.  Aprotinin is associated with a decrease in nitric oxide production during cardiopulmonary bypass. , 1997, Surgery.

[12]  M. Davies,et al.  Prospective, randomized, double-blind study of high-dose aprotinin in pediatric cardiac operations. , 1997, The Annals of thoracic surgery.

[13]  K. Watterson,et al.  "Low-dose" aprotinin modifies hemostasis but not proinflammatory cytokine release. , 1997, The Annals of thoracic surgery.

[14]  E. Bove,et al.  The Efficacy and Cost of Aprotinin in Children Undergoing Reoperative Open Heart Surgery , 1996, Anesthesia and analgesia.

[15]  M. Siimes,et al.  Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations. , 1996, The Journal of thoracic and cardiovascular surgery.

[16]  G. von Bernuth,et al.  Influence of low-dose aprotinin on the inflammatory reaction due to cardiopulmonary bypass in children. , 1996, The Annals of thoracic surgery.

[17]  F. Neumann,et al.  Platelet function in acute myocardial infarction treated with direct angioplasty. , 1996, Circulation.

[18]  G. Hill,et al.  Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. , 1995, The Journal of thoracic and cardiovascular surgery.

[19]  M. Jochum,et al.  Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. , 1993, The Journal of thoracic and cardiovascular surgery.

[20]  M. Jochum,et al.  Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. , 1990, Anesthesiology.

[21]  K. M. Taylor,et al.  EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERY , 1987, The Lancet.

[22]  W. Müller-Esterl,et al.  Monitoring of aprotinin plasma levels by an enzyme-linked immunosorbent assay (ELISA) , 1984 .